Try our Advanced Search for more refined results

In Re: Testosterone Replacement Therapy Products Liability Litigation

Track this case

Case overview

Case Number:

1:14-cv-01748

Court:

Illinois Northern

Nature of Suit:

367(Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability)

Judge:

Honorable Matthew F. Kennelly

Firms

Companies

Government Agencies

Sectors & Industries:

  1. November 05, 2020

    Actavis Can't Escape Testosterone Drug Warning Claims

    An Illinois federal judge won't give Actavis Inc. a quick win on claims that one of its testosterone drugs led to a user's stroke, finding that the company's duty to warn is not limited to a U.S. Food and Drug Administration-approved insert in the drug's packaging.

  2. January 02, 2020

    Actavis Sheds Some Claims But Can't Exit Testosterone Trial

    An Illinois federal judge has partially denied pharmaceutical giant Actavis' summary judgment motion and refused to bar certain expert testimony in what was to have been the first bellwether trial against that company over cardiovascular issues allegedly caused by a testosterone replacement therapy drug.

  3. September 10, 2018

    AbbVie Strikes Tentative Deal In Testosterone MDL

    AbbVie Inc., the last remaining company to face claims that it failed to warn patients about the hidden dangers of testosterone replacement therapy products, has reached a tentative deal to exit the multidistrict litigation, according to a Monday filing in Illinois federal court.

  4. July 05, 2018

    $140M Verdict Against AbbVie In Testosterone MDL Tossed

    An Illinois federal judge vacated a $140 million verdict against AbbVie Inc. from the second bellwether in multidistrict litigation over testosterone products on Thursday, saying the jury's finding for the company on the case's strict liability claim threw a wrench in the rest of its verdict.

  5. May 29, 2018

    Besins Cut Loose From Testosterone Replacement MDL

    An Illinois federal judge on Tuesday dismissed Thailand-based pharmaceutical company Besins Healthcare SA from multidistrict litigation over testosterone replacement therapies such as AbbVie Inc.'s AndroGel, which Besins manufactures outside the U.S.

  6. May 11, 2018

    Dozens Of Cases Cut From Testosterone Replacement MDL

    An Illinois federal judge tossed about 160 cases from the multidistrict litigation over testosterone replacement therapy products Friday after the plaintiffs did not respond to requests for more information on their claims against the pharmaceutical companies.

  7. February 26, 2018

    Plaintiffs Agree To Release Pfizer From Testosterone MDL

    Pharmaceutical giant Pfizer Inc. on Monday told an Illinois federal judge that it had come to an agreement with the plaintiffs suing the company to finally end its role in a massive multidistrict litigation over claims it and other drugmakers failed to warn consumers about risks accompanying its testosterone replacement drug.

  8. February 20, 2018

    Patient Says AbbVie's New Trial Needs To Be On All Claims

    A patient has urged an Illinois federal court to order a new trial on all of his claims rather than maintain its decision to hold a new trial on just one claim in the first bellwether case to reach a verdict in multidistrict litigation over testosterone replacement therapies including AbbVie Inc.'s AndroGel, noting the court determined the jury verdict awarding him $150 million in punitive damages was inconsistent.

  9. January 31, 2018

    AbbVie Seeks New Trial After $140M AndroGel Verdict

    AbbVie Inc. on Tuesday asked an Illinois federal judge for a new trial in the second bellwether case over claims the drugmaker failed to warn consumers about risks accompanying its testosterone treatment AndroGel, calling the $140 million verdict fatally inconsistent.

  10. December 21, 2017

    Where 5 Top MDLs Stand At The End Of 2017

    Multidistrict litigation dockets sizzled in 2017 with a spate of notable bellwether trials and a handful of attention-grabbing settlements, as well as centralization of litigation over some of the year's biggest corporate scandals.